TACSTD2 and neoplasm: More importantly, SG003 had no/weak cross-reactivity to bind CD38- tumor cells (e.g. 293 T) by flow cytometry detection (Fig. 4a), or a series of extracellular domain of many receptors/glycol-proteins (e.g. CD47, CD19, AXL, TROP2, GAS6, etc.)by ELISA detection (Fig. 4b).